TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Deconstructing Return on Equity into Operating Profitability, Asset Efficiency, Tax Retention, and Financial Leverage.
| Company | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|
| ★ AstraZeneca Pharma India LimitedActive | — | — | 0.002 |
| Alembic Limited(ALEMBICLTD) | 8.09 | 1.05 | 0 |
| Amrutanjan Health Care Limited(AMRUTANJAN) | 25.67 | 4.02 | 0 |
| Bajaj Healthcare Limited(BAJAJHCARE) | 47.93 | 2.03 | 0 |
| Anlon Healthcare Limited |
DuPont Analysis breaks down AstraZeneca Pharma India Limited's Return on Equity (15.0%) into core operational and financial drivers: Tax Burden (75.0%), Interest Burden (94.0%), EBIT Margin (17.1%), Asset Turnover (0.92x), and Financial Leverage (1.25x).
With a Debt-to-Equity of 0.25x and a Financial Leverage multiplier of 1.25x, AstraZeneca Pharma India Limited's ROE is predominantly driven by core operating profitability and pricing power (high quality earnings).
AstraZeneca Pharma India Limited generates a Return on Capital Employed (ROCE) of 18.0% versus an ROE of 15.0%, indicating efficient total capital utilization across both equity and debt capital.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.
| 26.55 |
| 3.67 |
| 0 |
| Anuh Pharma Limited(ANUHPHR) | 20.41 | 2.38 | 0 |